Readystate Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Readystate Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-46,520	Closed	-$1.2M	–	407
2025 Q3	$1.2M	Sell	46,520 -288,480	-86%	-$6.68M	0.05%	181
2025 Q2	$6.82M	Buy	+335,000	New	+$6.52M	0.21%	91
2025 Q1	–	Sell	-142,038	Closed	-$3.59M	–	625
2024 Q4	$3.59M	Sell	142,038 -37,480	-21%	-$1.02M	0.11%	185
2024 Q3	$6.1M	Buy	+179,518	New	+$6.84M	0.11%	275
2024 Q2	–	Sell	-49,457	Closed	-$2.08M	–	768
2024 Q1	$2.08M	Buy	+49,457	New	+$2.03M	0.03%	551

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Readystate Asset Management's CLDX Position: Q4 2025 in Review

Readystate Asset Management sold out of Celldex Therapeutics (CLDX) in Q4 2025, closing a stake of 46,520 shares — an estimated $1.2M sold.

Readystate Asset Management first reported a position in CLDX in Q1 2024 and held it in 5 quarters. The position peaked at $6.82M in Q2 2025. 185 funds tracked by Wall St. Rank hold CLDX as of Q4 2025.

Readystate Asset Management reported no remaining Celldex Therapeutics position as of Q4 2025 after selling out during the quarter.
Readystate Asset Management sold 46,520 Celldex Therapeutics shares in Q4 2025, an estimated $1.2M.
Readystate Asset Management first reported a position in Celldex Therapeutics in Q1 2024 and held it in 5 quarters.
Readystate Asset Management's Celldex Therapeutics position peaked at $6.82M in Q2 2025.
185 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2025.

Based on Readystate Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.